- Trials with a EudraCT protocol (10,880)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (38)
10,880 result(s) found for: Pregnancy.
Displaying page 1 of 544.
EudraCT Number: 2016-004981-24 | Sponsor Protocol Number: Plaquenil | Start Date*: 2017-04-12 | |||||||||||
Sponsor Name:Henriette Svarre Nielsen | |||||||||||||
Full Title: Hydroxychloroquin (Plaquenil) treatment of recurrent pregnancy loss – a randomized, double blinded, placebo controlled study | |||||||||||||
Medical condition: Recurrent pregnancy losses. Women with >3 subsequent pregnancy losses or 3 pregnancy losses of which one was a 2. trimester loss. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000419-34 | Sponsor Protocol Number: RC15_0475 | Start Date*: 2016-10-24 | |||||||||||
Sponsor Name:CHU de Nantes | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003124-41 | Sponsor Protocol Number: 219510 | Start Date*: 2023-03-27 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals SA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 3b, non-randomized, open label, multi-country, cohort study to describe the safety of study participants who received RSVPreF3 maternal vaccination (any dose) or controls from previous RSV ... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Pregnancy related outcomes and events in maternal participants who were vaccinated against RSV or received control, and in their infants | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FI (Completed) BE (Completed) DE (Completed) FR (Ongoing) ES (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003603-61 | Sponsor Protocol Number: 002 | Start Date*: 2017-07-19 | ||||||||||||||||
Sponsor Name: | ||||||||||||||||||
Full Title: Clinical trial on the administration of 3 doses of betamethasone (12 mg) in 18 hours apart in twin pregnancy patients with threatened preterm birth treated by Atosiban, rather than 2 doses of betam... | ||||||||||||||||||
Medical condition: Premature delivery in twin pregnancies | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000194-21 | Sponsor Protocol Number: 150/04 | Start Date*: 2004-12-31 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA | |||||||||||||
Full Title: Effetti della L-argina nella profilassi della ipertensione cronica dal secondo trimestre di gravidanza | |||||||||||||
Medical condition: Profilassi della ipertensione cronica dal secondo trimestre di gravidanza | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001747-69 | Sponsor Protocol Number: GEMII-1 | Start Date*: 2011-10-28 | |||||||||||
Sponsor Name:Monash University [...] | |||||||||||||
Full Title: Combination gefitinib and methotrexate to treat ectopic pregnancies II | |||||||||||||
Medical condition: Ectopic pregnancy or pregnancy of unknown location. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010759-29 | Sponsor Protocol Number: 001 | Start Date*: 2009-04-27 | ||||||||||||||||
Sponsor Name:Cliniques Universitaires Saint-Luc | ||||||||||||||||||
Full Title: étude clinique sur l’administration de 3 doses de betaméthasone (12mg) à 18 heures d’intervalle lors d’une menace d’accouchement prématuré dans les grossesses gémellaires traitées par Atosiban, plu... | ||||||||||||||||||
Medical condition: Premature delivery in twin pregnancies | ||||||||||||||||||
|
||||||||||||||||||
Population Age: In utero, Under 18, Adults | Gender: Female | |||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-003778-29 | Sponsor Protocol Number: CTU/2013/064 | Start Date*: 2014-01-30 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Combined Multi-Marker Screening and Randomised Patient Treatment with Aspirin for Evidence-based Pre-eclampsia Prevention | |||||||||||||
Medical condition: Pre-eclampsia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) BE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004192-12 | Sponsor Protocol Number: NL66079.029.18 | Start Date*: 2019-08-05 |
Sponsor Name:Amsterdam UMC, location VU medical Center | ||
Full Title: Oil- based versus water-based contrast media for hysterosalpingography (HSG) in infertile women with unevaluated indications: a randomized controlled trial | ||
Medical condition: The research population consists of infertile couples who have tried to conceive for at least 12 months, or have oligo- or anovulation. We will focus on women with ovulation disorders, or at high r... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004592-40 | Sponsor Protocol Number: 1 | Start Date*: 2020-11-20 | |||||||||||
Sponsor Name:University of Edinburgh [...] | |||||||||||||
Full Title: An open label exploratory study to assess the safety of using 100mg of methotrexate as a standard dose treatment for women with unruptured tubal ectopic pregnancy (OSPREY) | |||||||||||||
Medical condition: Ectopic Pregnancy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004112-10 | Sponsor Protocol Number: PROTECTA | Start Date*: 2020-12-16 |
Sponsor Name:Ghent University Hospital | ||
Full Title: Randomized controlled trial comparing micronized progesterone (Amelgen ®) 400 mg BID versus 400 mg TID for luteal support in artificial vitrified/warmed single blastocyst transfer cycles with low p... | ||
Medical condition: Patients who undergo artificial vitrified/warmed single blastocyst transfer cycles with low progesterone (defined as <10mcg/l) on day of embryo transfer. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-005206-19 | Sponsor Protocol Number: FFIS/2016/02/ST | Start Date*: 2017-05-26 | |||||||||||
Sponsor Name:Fundación para la Formación e Investigación Sanitaria (FFIS) | |||||||||||||
Full Title: Randomised Controlled Trial with Pravastatin versus Placebo for Prevention of Preeclampsia | |||||||||||||
Medical condition: Pre-eclampsia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005194-77 | Sponsor Protocol Number: Matimmunestudyversion2 | Start Date*: 2021-10-26 |
Sponsor Name:University of Antwerp | ||
Full Title: The optimal timing of vaccination in pregnancy: a multi-dimensional mechanistic approach to measure immune responses in pregnant women | ||
Medical condition: humoral and cellular immune responses to pertussis vaccine during pregnancy | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2008-001323-64 | Sponsor Protocol Number: 7/2008/O/Sper | Start Date*: 2008-03-12 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: PHASE III DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY ON THE EFFICACY OF URSODEOXYCHOLIC ACID FOR THE TREATMENT OF INTRAHEPATIC CHOLESTASIS OF PREGNANCY | |||||||||||||
Medical condition: INTRAHEPATIC CHOLESTASIS OF PREGNANCY | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001984-53 | Sponsor Protocol Number: ETHIG II | Start Date*: 2006-10-11 | |||||||||||
Sponsor Name:Friedrich-Schiller-Universität Jena | |||||||||||||
Full Title: Effectiveness of Dalteparin Therapy as Intervention in recurrent pregnancy loss | |||||||||||||
Medical condition: Pregnant women with a history of recurrent pregnancy loss, defined as: - 2 or more early (< 12 weeks of gestation) pregnancy losses or - 1 or more late (> 12 weeks of gestation) pregnancy loss | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019483-37 | Sponsor Protocol Number: PelleLindqvist | Start Date*: 2011-04-06 | |||||||||||||||||||||
Sponsor Name:Karolinska University Hospital | |||||||||||||||||||||||
Full Title: Vitamin D supplementation for prevention of placenta mediated pregnancy complications. | |||||||||||||||||||||||
Medical condition: We will try to prevent preeclampsia, groth restriction and prematurity by vitamin D supplementation given as one dose in mid pregnancy | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: | Gender: Female | ||||||||||||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001918-42 | Sponsor Protocol Number: 2009-107(Canadian) | Start Date*: 2014-01-17 | |||||||||||
Sponsor Name:Ottawa Hospital Research Institute | |||||||||||||
Full Title: Effect of folic acid supplementation in pregnancy on preeclampsia - Folic Acid Clinical Trial (FACT) A randomized, double-blind, placebo-controlled, Phase III, international multi-centre study of 4... | |||||||||||||
Medical condition: pre-eclampsia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000811-26 | Sponsor Protocol Number: STOPPRE | Start Date*: 2018-09-19 | |||||||||||
Sponsor Name:Vall D'Hebron Institut de Recerca (VHIR) | |||||||||||||
Full Title: A phase III, multicentric, Randomized, open-label, parallel-group clinical trial to detect false positives from first-trimester preeclampsia screening (StopPRE) at the second-trimester of pregnancy. | |||||||||||||
Medical condition: First-trimester pre-eclampsia patients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005130-22 | Sponsor Protocol Number: FFIS/2015/01/ST | Start Date*: 2016-08-03 | |||||||||||
Sponsor Name:Fundación para la Formación e Investigación Sanitaria (FFIS) | |||||||||||||
Full Title: Randomised Controlled Trial with Pravastatin versus Placebo for Prevention of Pre-eclampsia | |||||||||||||
Medical condition: Pre-eclampsia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) BE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000084-40 | Sponsor Protocol Number: NT-05 | Start Date*: 2014-04-07 | |||||||||||
Sponsor Name:Nora Therapeutics, Inc. | |||||||||||||
Full Title: A randomized, double blind, multi-center, placebo-controlled study to evaluate the efficacy, safety, and tolerability of NT100 in pregnant women with a history of unexplained recurrent pregnancy lo... | |||||||||||||
Medical condition: Unexplained recurrent pregnancy loss. A distinct disorder from sporadic pregnancy loss and is characterized by the loss of multiple pregnancies | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
